A Phase I-II Study of HM781-36B(Poziotinib)Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
Conditions
HER-2 Positive Advanced Gastric Cancer
Conditions: official terms
Stomach Neoplasms
Conditions: Keywords
HM781-36B, Paclitaxel, Trastuzumab
Study Type
Interventional
Study Phase
Phase 1/Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: HM781-36B(Poziotinib) Type: Drug
Name: Paclitaxel Type: Drug
Name: Trastuzumab Type: Drug
Overall Status
Recruiting
Summary
[Phase I] The main objective of this study is to evaluate the safety, tolerability and determine the Recommended Dose (RD) of HM781-36B(Poziotinib)combined with Paclitaxel and Trastuzumab

[Phase II] The main objective of this study is to evaluate anticancer activity through determination of response rate of HM781-36B(Poziotinib)combined with Paclitaxel and Trastuzumab in patients with HER-2 positive advanced gastric cancer
Detailed Description
Besides the main objectives, there are other objectives as follows:

[Phase I]

1. To assess the pharmacokinetic profile of HM781-36B(Poziotinib) combined with Paclitaxel and Trastuzumab

2. To evaluate anticancer activity of HM781-36B(Poziotinib) combined with Paclitaxel and Trastuzumab in patients with HER-2 positive advanced gastric cancer

3. To evaluate PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR (Duration of Overall Response)

[Phase II]

1. To assess the safety, tolerability of HM781-36B(Poziotinib) combined with Paclitaxel and Trastuzumab

2. To evaluate tumor response through determination of disease control rate , PFS(Progression-Free Survival), TTP (Time To Tumor Progression), and DOR (Duration of Overall Response)
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 19 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Histologically or cytologically confirmed advanced gastric cancer including gastroesophageal junction adenocarcinoma

2. At least one measurable lesion defined by RECIST(v1.1)

3. FISH+ or IHC3+ (regardless of FISH results)

4. Age≥19

5. ECOG ≤ 2

6. Life expectancy ≥ 12 weeks

7. Adequate bone marrow and no abnormal heart and lung function

8. No radiotherapy, other anticancer drugs or immunotherapy is allowed during this study

9. Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up assessments and procedures

Exclusion Criteria:

1. Patients with a hitory of hypersensitivity to Trastuzumab and who have been treated with medicine including Cremophor EL

2. Patients who have a current active malignancy other than gastric adenocarcinoma (with exception of non-melanoma skin cancer or cervical cancer in situ)

3. Patients who have previously received taxane-based chemotherapy

4. The presence of central nervous system metastases

5. Patients who have a blood tumor such as leukemia, or who had previously received, or are planning to receive, the bone marrow transplant

6. Patients with uncontrolled infection

7. Patients who have GI malabsorption or difficulty taking oral medication

8. Patients with following diseases are excluded:

9. Patients with psychiatric or congenital disorder which can affect adherence or make hard to follow the requirements of the protocol

10. Pregnant or breastfeeding women or women of childbearing who do not use an appropriate method of contraception (male patient should also use an appropriate method of contraception)
Location
Seoul National University Hospital
Seoul, Korea, Republic of
Status: Recruiting
Contact: Yung-Jue Bang - bangyj@snu.ac.kr
Start Date
November 2012
Completion Date
February 2015
Sponsors
Hanmi Pharmaceutical Company Limited
Source
Hanmi Pharmaceutical Company Limited
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page